Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
421-440 of 2,120 trials

Advanced Breast Cancer: Capivasertib with CDK4/6 Inhibitors

We are studying a new treatment combining capivasertib with CDK4/6 inhibitors and fulvestrant for patients with advanced hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this combination improves treatment outcomes compared to standard therapies.

Hormone Receptor-Positive and HER2-Negative Breast Cancer3-6 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Acute Myeloid Leukemia: CHIP-AML22 Trial

We are studying new treatment options for children and adolescents with newly diagnosed AML to see if they improve survival and reduce side effects compared to standard therapies.

Acute Myeloid Leukemia6-12 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesHematologyPediatrics

HER2-Positive Oligo-Metastatic Breast Cancer: T-DXd Treatment Study

We are investigating how well T-DXd works in combination with other treatments for patients with HER2-positive oligo-metastatic breast cancer. The study will also look at safety and how it affects cancer markers in the blood.

HER2-Positive Metastatic Breast Cancer6-12 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Non-Seminomatous Germ-Cell Tumors: Personalized Treatment Study

We are exploring new treatment strategies for young adults with poor-prognosis non-seminomatous germ-cell tumors. This study aims to improve outcomes through personalized care and early assessments.

Germ Cell Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Long-Term Study of Delandistrogene Moxeparvovec (SRP-9001)

We are assessing the long-term safety and effectiveness of delandistrogene moxeparvovec in individuals who previously participated in a clinical study. This research aims to understand how the treatment continues to affect participants over time.

Duchenne Muscular Dystrophy>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyOrthopedics and Traumatology

Multiple Myeloma: HyQvia for Infection Prevention

We are studying whether HyQvia can help reduce infections in patients with newly diagnosed multiple myeloma who are not eligible for a transplant. The trial aims to see if it improves survival and quality of life compared to standard care.

Multiple Myeloma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyInfectious Diseases

Lung Cancer Treatment Comparison: Atezolizumab vs. Pembrolizumab

We are studying two treatment combinations for patients with metastatic TTF-1 negative lung adenocarcinoma to see which one may improve survival. This trial compares atezolizumab with carboplatin and nab-paclitaxel against pembrolizumab with platinum and pemetrexed.

Metastatic Lung Adenocarcinoma>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOncologyPulmonology

Advanced Solid Tumors: Amivantamab Treatment Study

We are studying a new treatment called amivantamab for patients with advanced or metastatic solid tumors, including those with EGFR-mutated lung cancer. The goal is to see how well it works when combined with other therapies.

Non-small Cell Lung CancerEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Non-Squamous NSCLC: Dato-DXd with Rilvegostomig

We are studying if a new treatment combination is safe and effective compared to pembrolizumab for patients with advanced non-squamous lung cancer. This trial is for those with high PD-L1 levels and no specific genetic changes.

Non-Small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Extrapulmonary Small Cell Carcinoma: Durvalumab Combination Therapy

We are studying a new treatment combining durvalumab with carboplatin or cisplatin and etoposide for patients with extensive stage extrapulmonary small cell carcinoma. The goal is to see if this combination improves survival and quality of life compared to standard treatments.

Extensive Stage Extrapulmonary Small Cell CarcinomaEfficacy phase (II)No PlaceboStandard MedicinesOncology

Pulmonary Arterial Hypertension: Treprostinil Sodium for Kids

We are studying the safety and tolerability of a new preservative-free medication for children with pulmonary arterial hypertension. The trial also looks at how it may improve their quality of life and symptoms.

Pulmonary Arterial Hypertension3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemotePediatricsPulmonology

ASP1570 for Advanced Solid Tumors

We are studying a new treatment, ASP1570, alone and with pembrolizumab for adults with advanced solid tumors. The trial aims to evaluate safety, tolerability, and potential anti-tumor effects.

Advanced Solid TumorsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Preclinical Alzheimer's Disease: JNJ-64042056 Immunotherapy

We are studying a new treatment to see if it may help slow cognitive decline in people with preclinical Alzheimer's disease. Participants will receive either the treatment or a placebo to compare effects.

Preclinical Alzheimer's Disease>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesNeurologyPsychiatry

Tocilizumab for Acute Chest Syndrome in Sickle Cell Disease

We are studying whether tocilizumab can help patients with sickle cell disease recover from acute chest syndrome faster and safely. The trial includes both children and adults to assess its effectiveness and safety.

Sickle Cell Disease>2 yearsConfirmation phase (III)Standard MedicinesHematologyPulmonology

Colorectal Cancer: ABBV-400 Treatment Study

We are studying a new drug, ABBV-400, combined with standard treatments for adults with advanced colorectal cancer. The goal is to assess its safety and effectiveness in patients who have already been treated.

Metastatic Colorectal CancerEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Uveitis Treatment: Adalimumab vs. Mycophenolate Mofetil

We are studying whether adalimumab can improve outcomes for people with steroid-dependent non-infectious uveitis compared to the standard treatment. This trial will help us understand the effectiveness and safety of both medications.

Uveitis>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementOphthalmologyRheumatology

IVF Luteal Phase Support: GnRH Agonist vs. hCG

We are studying whether a GnRH agonist can improve live birth rates and reduce miscarriages in women undergoing IVF compared to traditional hCG and progesterone support.

Assisted Reproductive Technology≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesGynecology and Obstetrics

Childhood Onset Nephrotic Syndrome: Obinutuzumab vs. MMF

We are studying whether obinutuzumab is more effective and safer than MMF for children with childhood onset idiopathic nephrotic syndrome. We will also look at how these treatments affect fatigue and quality of life.

Childhood Idiopathic Nephrotic Syndrome1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology

Efruxifermin for Non-Cirrhotic NASH/MASH

We are studying whether Efruxifermin can improve liver health and reduce fibrosis in people with Non-Cirrhotic NASH or MASH. Participants will be compared to those receiving a placebo to assess safety and effectiveness.

Non-alcoholic Fatty Liver DiseaseHepatic Fibrosis1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesEndocrinologyHepatology

S. aureus Bacteremia: Cloxacillin Dosing Study

We are investigating whether kidney function can help identify patients who may need adjusted doses of cloxacillin. This study aims to ensure safer and more effective treatment for those with S. aureus bacteremia.

Staphylococcus aureus BacteremiaMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesNephrology